Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html

Study Counts

Type Study_count
Total_Studies 121
interventional 87
Observational 30
Registry 4

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 47
Behavioral 10
Drug|Other 6
Other 5
Drug|placebo 4
Device 3
Biological 2
Biological|Other|Procedure 2
Diagnostic Test 2
Behavioral|Drug|placebo 1
Biological|Drug|Procedure|Radiation 1
Device|Other 1
Device|Procedure 1
Drug|Procedure 1
Genetic|Other|Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 60
France 6
United Kingdom 4
United States|Canada 3
China 2
NA 2
United States|Australia 2
Brazil 1
Denmark 1
Japan 1
Portugal 1
Sweden 1
United States|Australia|Canada|New Zealand 1
United States|France|Spain 1
United States|Germany 1

Sites per Study

Site_count Study_Count
1 51
2 6
3 4
4 2
5 1
6 2
7 1
9 1
11 1
12 5
13 1
15 2
16 1
17 3
21 1
22 1
43 1
52 1
53 1
126 1

Phase

Phase Study_Count
Phase 2 39
N/A 20
Phase 1 13
Phase 1/Phase 2 7
Early Phase 1 3
Phase 3 3
Phase 4 2

Number of Arms

Number_of_Arms Count_of_Studies
1 47
2 27
4 3
6 3
NA 7

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.3 Phase.4
Min. 6.0 5.00 9.00 21.00000 4.00000 67.0000 80.0
1st Qu. 8.5 30.00 10.00 52.50000 19.25000 83.5000 122.5
Median 11.0 48.00 22.50 81.00000 24.00000 100.0000 165.0
Mean 15.0 86.55 23.00 83.71429 44.71053 152.3333 165.0
3rd Qu. 19.5 142.75 29.25 99.50000 49.50000 195.0000 207.5
Max. 28.0 286.00 52.00 180.00000 320.00000 290.0000 250.0

Trial Group Type

group_type Group_Count
Experimental 97
Placebo Comparator 13
Active Comparator 12
NA 7
Other 5
No Intervention 3
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 52
Parallel Assignment 26
Crossover Assignment 4
NA 3
Sequential Assignment 2

Primary Purpose

primary_purpose Study_Count
Treatment 67
Diagnostic 5
Prevention 4
Supportive Care 4
Basic Science 2
Other 2
NA 2
Screening 1

Observational Studies

Studies by Country

Country Study_Count
United States 23
France 3
United Kingdom 2
NA 1
United States|Canada 1

Sites per Study

Site_count Study_Count
1 28
3 1
4 1

Enrollment Metrics

Measure Observational
Min 5.0000
1st Qu 31.5000
Median 106.0000
Mean 348.4667
3rd Qu 348.2500
Max 3000.0000

Observation Model

observational_model Study_Count
Cohort 19
Case-Only 3
Family-Based 3
NA 2
Case-Control 1
Case Control 1
Other 1

Time Perspective

time_perspective Study_Count
Prospective 25
Cross-Sectional 2
Retrospective 2
Other 1

Registries

Studies by Country

Country Study_Count
United States 3
Germany 1

Sites per Study

Site_count Study_Count
1 4

Enrollment Metrics

Measure Registries
Min 70.00
1st Qu 767.50
Median 1695.50
Mean 3365.25
3rd Qu 4293.25
Max 10000.00

Registry Model

observational_model Study_Count
Case-Control 1
Case-Only 1
Cohort 1
Other 1

Time Perspective

time_perspective Study_Count
Other 3
Prospective 1

Follow-up

target_duration Study_Count
50 Years 3
5 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT04461886 A Long-term Study of NPC-12G Gel in Neurofibromatosis Type I https://ClinicalTrials.gov/show/NCT04461886 Recruiting Nobelpharma 2022-04-30
NCT03406208 Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing https://ClinicalTrials.gov/show/NCT03406208 Recruiting Massachusetts General Hospital 2022-01-30
NCT03820778 Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1 https://ClinicalTrials.gov/show/NCT03820778 Enrolling by invitation Children’s National Research Institute 2022-07-12
NCT03326388 Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours https://ClinicalTrials.gov/show/NCT03326388 Recruiting Great Ormond Street Hospital for Children NHS Foundation Trust 2020-08-31
NCT03310996 Non-invasive Stimulation in Neurofibromatosis Type 1 https://ClinicalTrials.gov/show/NCT03310996 Completed University of Manchester 2018-06-30
NCT03190915 Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia https://ClinicalTrials.gov/show/NCT03190915 Recruiting National Cancer Institute (NCI) 2021-12-31
NCT03095248 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors https://ClinicalTrials.gov/show/NCT03095248 Recruiting Children’s Hospital Medical Center, Cincinnati 2021-05-31
NCT03090971 Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 https://ClinicalTrials.gov/show/NCT03090971 Completed Fundação Educacional Serra dos Órgãos 2017-03-23
NCT02964884 Interventions for Reading Disabilities in NF1 https://ClinicalTrials.gov/show/NCT02964884 Recruiting Vanderbilt University 2020-11-30
NCT02944032 Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1 https://ClinicalTrials.gov/show/NCT02944032 Recruiting Children’s National Research Institute 2020-09-30
NCT02839720 Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma https://ClinicalTrials.gov/show/NCT02839720 Recruiting National Cancer Institute (NCI) 2021-12-31
NCT02831257 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas https://ClinicalTrials.gov/show/NCT02831257 Active, not recruiting Massachusetts General Hospital 2020-03-31
NCT02811718 Resiliency Training for Patients With NF2 Via Videoconferencing With Skype https://ClinicalTrials.gov/show/NCT02811718 Completed Massachusetts General Hospital 2018-06-30
NCT02728388 Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II https://ClinicalTrials.gov/show/NCT02728388 Recruiting Medical College of Wisconsin 2022-08-31
NCT02718131 A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1) https://ClinicalTrials.gov/show/NCT02718131 Active, not recruiting University of Alabama at Birmingham 2021-05-31
NCT02700230 Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT02700230 Recruiting Mayo Clinic 2021-06-15
NCT02407405 MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas https://ClinicalTrials.gov/show/NCT02407405 Recruiting National Institutes of Health Clinical Center (CC) 2021-08-31
NCT02390752 PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) https://ClinicalTrials.gov/show/NCT02390752 Recruiting National Institutes of Health Clinical Center (CC) 2021-12-01
NCT02211768 Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 https://ClinicalTrials.gov/show/NCT02211768 Completed National Institutes of Health Clinical Center (CC) 2017-02-15
NCT02422732 Functional Imaging and Reading Deficit in Children With NF1 https://ClinicalTrials.gov/show/NCT02422732 Completed University Hospital, Toulouse 2015-04-30
NCT02415153 Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors https://ClinicalTrials.gov/show/NCT02415153 Active, not recruiting National Cancer Institute (NCI) 2019-07-01
NCT02397967 Reading Disability in Children With NF1 https://ClinicalTrials.gov/show/NCT02397967 Completed University Hospital, Toulouse 2014-04-30
NCT02387177 Resiliency Training for Adolescent Neurofibromatosis Patients Via Videoconferencing With Skype https://ClinicalTrials.gov/show/NCT02387177 Completed Massachusetts General Hospital 2017-12-31
NCT02332902 Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T https://ClinicalTrials.gov/show/NCT02332902 Completed The University of Texas Health Science Center, Houston 2016-03-31
NCT02298270 Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype https://ClinicalTrials.gov/show/NCT02298270 Completed Massachusetts General Hospital 2015-07-31
NCT02246231 Effect of Implant Position on Magnetic Resonance Image Distortion https://ClinicalTrials.gov/show/NCT02246231 Completed Manchester University NHS Foundation Trust 2015-01-31
NCT02129647 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas https://ClinicalTrials.gov/show/NCT02129647 Active, not recruiting NYU Langone Health 2019-02-24
NCT02104323 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors https://ClinicalTrials.gov/show/NCT02104323 Completed Beijing Tiantan Hospital 2016-04-30
NCT02101736 Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults https://ClinicalTrials.gov/show/NCT02101736 Recruiting University of Alabama at Birmingham 2021-05-31
NCT02096471 MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1 https://ClinicalTrials.gov/show/NCT02096471 Completed University of Alabama at Birmingham 2017-08-09
NCT01275586 Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas https://ClinicalTrials.gov/show/NCT01275586 Completed Indiana University 2016-07-31
NCT03871257 A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma https://ClinicalTrials.gov/show/NCT03871257 Recruiting National Cancer Institute (NCI) 2027-05-01
NCT01968590 Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1) https://ClinicalTrials.gov/show/NCT01968590 Recruiting University of Utah 2022-10-31
NCT01851135 Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 https://ClinicalTrials.gov/show/NCT01851135 Completed Nantes University Hospital 2016-04-30
NCT01767792 Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas https://ClinicalTrials.gov/show/NCT01767792 Active, not recruiting University of Alabama at Birmingham 2019-04-30
NCT01682811 Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1) https://ClinicalTrials.gov/show/NCT01682811 Completed Medical College of Wisconsin 2016-10-31
NCT01633008 Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain https://ClinicalTrials.gov/show/NCT01633008 Completed National Institutes of Health Clinical Center (CC) 2014-05-01
NCT01490476 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients https://ClinicalTrials.gov/show/NCT01490476 Completed Assistance Publique - Hôpitaux de Paris 2016-04-30
NCT01419639 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 https://ClinicalTrials.gov/show/NCT01419639 Completed NYU Langone Health 2012-12-31
NCT01412892 Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas https://ClinicalTrials.gov/show/NCT01412892 Completed Assistance Publique - Hôpitaux de Paris 2013-10-31
NCT01345136 Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma https://ClinicalTrials.gov/show/NCT01345136 Active, not recruiting Jonsson Comprehensive Cancer Center 2021-02-01
NCT04283669 Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas https://ClinicalTrials.gov/show/NCT04283669 Active, not recruiting University of Alabama at Birmingham 2025-08-18
NCT04201457 A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration https://ClinicalTrials.gov/show/NCT04201457 Recruiting Pediatric Brain Tumor Consortium 2025-02-28
NCT04085159 Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis https://ClinicalTrials.gov/show/NCT04085159 Recruiting Shenzhen Geno-Immune Medical Institute 2021-01-31
NCT03981510 Comparison of Gastrointestinal Motility in Healthy Children and Children With Constipation https://ClinicalTrials.gov/show/NCT03981510 Recruiting University of Aarhus 2023-12-31
NCT03975829 Pediatric Long-Term Follow-up and Rollover Study https://ClinicalTrials.gov/show/NCT03975829 Recruiting Novartis 2022-12-23
NCT03962543 MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas https://ClinicalTrials.gov/show/NCT03962543 Recruiting SpringWorks Therapeutics, Inc. 2022-07-31
NCT03888248 Whole-body Vibration in Children With Neurofibromatosis Type 1 https://ClinicalTrials.gov/show/NCT03888248 Enrolling by invitation Manchester University NHS Foundation Trust 2020-07-31
NCT03873610 Resiliency Training in Adolescents With NF1 and NF2 https://ClinicalTrials.gov/show/NCT03873610 Recruiting Massachusetts General Hospital 2022-04-01
NCT03826940 From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1 https://ClinicalTrials.gov/show/NCT03826940 Recruiting University of Coimbra 2020-01-31
NCT03741101 Treatment of NF1-related Plexiform Neurofibroma With Trametinib https://ClinicalTrials.gov/show/NCT03741101 Recruiting Region Skane 2022-07-31
NCT03688568 Study of Imatinib in Children With Neurofibromatosis and Airway Tumors https://ClinicalTrials.gov/show/NCT03688568 Recruiting Indiana University 2020-09-01
NCT03672838 A Single Center Pilot Study to Assess the Intra-observer Reliability of Measuring Muscle Strength Using a Hand Held Dynamometer in Children and Adults With Neurofibromatosis Type 1 (NF1) and Type 2 (NF2) https://ClinicalTrials.gov/show/NCT03672838 Recruiting NYU Langone Health 2020-06-30
NCT03649165 A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants https://ClinicalTrials.gov/show/NCT03649165 Completed AstraZeneca 2018-10-21
NCT03531814 Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials https://ClinicalTrials.gov/show/NCT03531814 Recruiting National Institutes of Health Clinical Center (CC) 2021-09-30
NCT03433183 SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors https://ClinicalTrials.gov/show/NCT03433183 Recruiting Sarcoma Alliance for Research through Collaboration 2021-09-30
NCT01207687 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) https://ClinicalTrials.gov/show/NCT01207687 Completed National Cancer Institute (NCI) 2013-02-28
NCT01140360 Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas https://ClinicalTrials.gov/show/NCT01140360 Completed Indiana University 2016-08-31
NCT01125046 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas https://ClinicalTrials.gov/show/NCT01125046 Active, not recruiting Northwestern University 2019-07-31
NCT01089101 Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma https://ClinicalTrials.gov/show/NCT01089101 Recruiting National Cancer Institute (NCI) 2022-12-31
NCT01058330 Effects of Physical Training on Bone and Muscle Quality, Muscle Strength, and Motor Coordination in Children With NF1 https://ClinicalTrials.gov/show/NCT01058330 Completed Shriners Hospitals for Children 2014-02-28
NCT01031901 Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1) https://ClinicalTrials.gov/show/NCT01031901 Completed The University of Texas Health Science Center, Houston 2011-02-28
NCT00973739 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors https://ClinicalTrials.gov/show/NCT00973739 Completed NYU Langone Health 2012-10-31
NCT00901849 Tarceva/Rapamycin for Children With Low-grade Gliomas With or Without Neurofibromatosis Type 1 (NF1) https://ClinicalTrials.gov/show/NCT00901849 Completed Children’s National Research Institute 2010-07-31
NCT00865644 Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1 https://ClinicalTrials.gov/show/NCT00865644 Completed Massachusetts General Hospital 2010-04-30
NCT00853580 A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1 https://ClinicalTrials.gov/show/NCT00853580 Completed University of Alabama at Birmingham 2014-05-31
NCT01553149 Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma https://ClinicalTrials.gov/show/NCT01553149 Active, not recruiting National Cancer Institute (NCI) 2020-06-30
NCT01673009 Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas https://ClinicalTrials.gov/show/NCT01673009 Completed Indiana University 2011-12-31
NCT01362803 AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors https://ClinicalTrials.gov/show/NCT01362803 Active, not recruiting National Institutes of Health Clinical Center (CC) 2019-03-29
NCT03231306 Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas https://ClinicalTrials.gov/show/NCT03231306 Recruiting University of Alabama at Birmingham 2022-12-31
NCT02471339 Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain https://ClinicalTrials.gov/show/NCT02471339 Active, not recruiting National Institutes of Health Clinical Center (CC) 2021-04-30
NCT00754780 Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1 https://ClinicalTrials.gov/show/NCT00754780 Completed Mayo Clinic 2004-08-31
NCT00727233 Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas https://ClinicalTrials.gov/show/NCT00727233 Completed National Institutes of Health Clinical Center (CC) 2011-06-16
NCT00657202 Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 https://ClinicalTrials.gov/show/NCT00657202 Completed Massachusetts General Hospital 2009-10-31
NCT00634270 A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas https://ClinicalTrials.gov/show/NCT00634270 Completed University of Alabama at Birmingham 2014-11-30
NCT00624234 Neurobiology and Treatment of Reading Disability in NF-1 https://ClinicalTrials.gov/show/NCT00624234 Completed Vanderbilt University 2013-03-31
NCT00589784 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma https://ClinicalTrials.gov/show/NCT00589784 Completed Memorial Sloan Kettering Cancer Center 2014-10-31
NCT00352599 Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1) https://ClinicalTrials.gov/show/NCT00352599 Completed University of California, Los Angeles 2014-03-31
NCT00352495 Vinblastine and Carboplatin in Treating Young Patients With Newly Diagnosed or Recurrent Low-Grade Glioma https://ClinicalTrials.gov/show/NCT00352495 Completed Children’s Oncology Group 2011-09-30
NCT00304083 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors https://ClinicalTrials.gov/show/NCT00304083 Completed Sarcoma Alliance for Research through Collaboration 2014-06-30
NCT00169611 NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate https://ClinicalTrials.gov/show/NCT00169611 Completed Hospices Civils de Lyon 2011-01-31
NCT00076102 Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas https://ClinicalTrials.gov/show/NCT00076102 Completed National Institutes of Health Clinical Center (CC) 2010-04-01
NCT00053937 Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas https://ClinicalTrials.gov/show/NCT00053937 Completed National Cancer Institute (NCI) NA
NCT00030264 Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas https://ClinicalTrials.gov/show/NCT00030264 Completed Children’s Hospital of Philadelphia 2013-12-31
NCT00030043 An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors https://ClinicalTrials.gov/show/NCT00030043 Completed FDA Office of Orphan Products Development NA
NCT00021541 R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas https://ClinicalTrials.gov/show/NCT00021541 Completed National Institutes of Health Clinical Center (CC) 2009-02-19
NCT00004437 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 https://ClinicalTrials.gov/show/NCT00004437 Completed FDA Office of Orphan Products Development NA

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03298438 Study About Annoucement of the Diagnosis of Neurofibromatosis 1 in de Novo Forms https://ClinicalTrials.gov/show/NCT03298438 Completed University Hospital, Brest 2016-12-31
NCT03050268 Familial Investigations of Childhood Cancer Predisposition https://ClinicalTrials.gov/show/NCT03050268 Recruiting St. Jude Children’s Research Hospital 2037-03-31
NCT00026780 Eligibility Screening for a NCI Pediatric Oncology Branch Research Study https://ClinicalTrials.gov/show/NCT00026780 Enrolling by invitation National Institutes of Health Clinical Center (CC) NA
NCT02544022 Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs) https://ClinicalTrials.gov/show/NCT02544022 Recruiting National Institutes of Health Clinical Center (CC) 2021-02-28
NCT02479360 Reliability of Functional Outcome Measures in Neurofibromatosis 1 https://ClinicalTrials.gov/show/NCT02479360 Completed Guy’s and St Thomas’ NHS Foundation Trust 2015-09-30
NCT02435628 Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With NF https://ClinicalTrials.gov/show/NCT02435628 Completed Massachusetts General Hospital 2016-09-30
NCT02153931 Internet Support Group for Parents of a Child With Neurofibromatosis Type 1 https://ClinicalTrials.gov/show/NCT02153931 Completed National Institutes of Health Clinical Center (CC) 2015-04-06
NCT01776125 Genetic Evaluation of NF1 and Scoliosis Patients https://ClinicalTrials.gov/show/NCT01776125 Completed University of Minnesota 2015-08-31
NCT01707836 Neurofibromatosis Type 1 Brain Tumor Genetic Risk https://ClinicalTrials.gov/show/NCT01707836 Completed Washington University School of Medicine 2017-05-08
NCT01702922 Relationship Stressors in Parents of Children With Cancer or Neurofibromatosis Type 1 (NF1) https://ClinicalTrials.gov/show/NCT01702922 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT01639950 Validating Pain Scales in Children and Young Adults https://ClinicalTrials.gov/show/NCT01639950 Completed National Institutes of Health Clinical Center (CC) NA
NCT01595139 MicroRNAs in Patients With Neurofibromatosis Type 1 https://ClinicalTrials.gov/show/NCT01595139 Completed Ann & Robert H Lurie Children’s Hospital of Chicago 2015-07-31
NCT01445314 Analysis of Data Collected From Individuals Administered Neurobehavioral Assessments https://ClinicalTrials.gov/show/NCT01445314 Enrolling by invitation National Institutes of Health Clinical Center (CC) NA
NCT04212351 Frameshift Peptides of Children With NF1 https://ClinicalTrials.gov/show/NCT04212351 Recruiting Children’s National Research Institute 2021-04-11
NCT04153344 Function of the Pigment Epithelium in Patients With Type 1 Neurofibromatosis https://ClinicalTrials.gov/show/NCT04153344 Recruiting Assistance Publique - Hôpitaux de Paris 2021-05-11
NCT03893643 Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15 https://ClinicalTrials.gov/show/NCT03893643 Recruiting Centre Hospitalier Universitaire de Nice 2022-12-31
NCT03617276 Reliability of Functional Outcome Measures in Neurofibromatosis 2 https://ClinicalTrials.gov/show/NCT03617276 Completed Guy’s and St Thomas’ NHS Foundation Trust 2017-05-17
NCT01222728 Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients https://ClinicalTrials.gov/show/NCT01222728 Completed National Institutes of Health Clinical Center (CC) NA
NCT00924196 Natural History Study of Patients With Neurofibromatosis Type I https://ClinicalTrials.gov/show/NCT00924196 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT00844129 Spinal Abnormalities in Neurofibromatosis Type 1 (NF1) https://ClinicalTrials.gov/show/NCT00844129 Completed University of Utah 2012-12-31
NCT01800032 PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1) https://ClinicalTrials.gov/show/NCT01800032 Active, not recruiting UNC Lineberger Comprehensive Cancer Center 2020-12-31
NCT00314119 Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 https://ClinicalTrials.gov/show/NCT00314119 Completed National Institutes of Health Clinical Center (CC) NA
NCT02680431 Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1 https://ClinicalTrials.gov/show/NCT02680431 Enrolling by invitation Turku University Hospital 2020-12-31
NCT00684398 Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I https://ClinicalTrials.gov/show/NCT00684398 Completed National Institutes of Health Clinical Center (CC) NA
NCT00667836 Multi-center Project: Spinal Abnormalities in Neurofibromatosis Type1 (NF1) Patients https://ClinicalTrials.gov/show/NCT00667836 Completed Shriners Hospitals for Children 2009-09-30
NCT00598351 Natural History Study of Patients With Neurofibromatosis Type 2 https://ClinicalTrials.gov/show/NCT00598351 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT00508235 Quality of Friendships in Children With Neurofibromatosis https://ClinicalTrials.gov/show/NCT00508235 Completed M.D. Anderson Cancer Center 2009-07-31
NCT00303368 Neurofibromatosis Type 1 (NF1) and Tibial Dysplasia https://ClinicalTrials.gov/show/NCT00303368 Completed Shriners Hospitals for Children 2014-01-31
NCT00111384 Study of Disease Severity in Adults With Neurofibromatosis Type 1 (NF1) https://ClinicalTrials.gov/show/NCT00111384 Active, not recruiting National Institutes of Health Clinical Center (CC) NA
NCT00006435 Study of Plexiform Neurofibromas in Neurofibromatosis Type 1 https://ClinicalTrials.gov/show/NCT00006435 Completed National Institutes of Health Clinical Center (CC) 2007-09-07

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03210285 WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data https://ClinicalTrials.gov/show/NCT03210285 Completed University Hospital Tuebingen 2018-04-01
NCT01885767 Neurofibromatosis (NF) Registry Portal https://ClinicalTrials.gov/show/NCT01885767 Recruiting The Children’s Tumor Foundation 2022-06-30
NCT01410006 Neurofibromatosis Type 1 Patient Registry https://ClinicalTrials.gov/show/NCT01410006 Completed Washington University School of Medicine 2017-07-31
NCT04395495 RASopathy Biorepository https://ClinicalTrials.gov/show/NCT04395495 Recruiting Children’s Hospital Medical Center, Cincinnati 2065-12-31